alpha-aminopyridine has been researched along with Myeloproliferative Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, JF; Guo, C; Li, B; Liang, AB; Wu, H; Zhou, J; Zhou, LL | 1 |
| Artz, AS; Cahill, K; Charnot-Katsikas, A; Gurbuxani, S; Kosuri, S; Larson, RA; Liu, H; Odenike, O; Patel, AA; Segal, J; Stock, W; Thirman, M | 1 |
| Hubbard, SR; Silvennoinen, O | 1 |
3 other study(ies) available for alpha-aminopyridine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2
Topics: Aminopyridines; Animals; Binding Sites; Blotting, Western; Case-Control Studies; Cell Count; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA Methyltransferase 3A; Down-Regulation; Exons; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Janus Kinase 2; K562 Cells; Mice; MicroRNAs; Monocytes; Mutation; Myeloproliferative Disorders; Promoter Regions, Genetic; Pyrazoles; Pyridazines; Signal Transduction; STAT5 Transcription Factor; Transcription, Genetic; Tumor Stem Cell Assay; Tumor Suppressor Proteins; U937 Cells | 2021 |
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.
Topics: Aged; Aged, 80 and over; Aminopyridines; Female; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Treatment Outcome; Triazines | 2020 |
Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Dexamethasone; Drug Resistance, Neoplasm; Humans; Janus Kinase 2; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2015 |